NCT07048262 - Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB) | Biotech Hunter

Enrollment

450

Participants

Timeline

Start Date

September 27, 2025

Primary Completion Date

February 28, 2028

Study Completion Date

March 28, 2028

Conditions

Non-cystic Fibrosis Bronchiectasis

Interventions

BIOLOGICAL

CSL787

CSL787 high or low doses once daily (QD) will be administered via inhalation over a period of \>= 6 months but not exceeding 12 months.

DRUG

Placebo

Participants will receive a matching volume of placebo QD over a period of \>= 6 months but not exceeding 12 months.

DEVICE

Nebulizer

The nebulizer is a CE-marked device.